EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Precision-guided treatment in high-risk pediatric cancers

Loretta M S Lau iD, Dong-Anh Khuong-Quang iD, Chelsea Mayoh iD, Marie Wong iD, Paulette Barahona, Pamela Ajuyah, Akanksha Senapati, Sumanth Nagabushan iD, Alexandra Sherstyuk, Ann-Kristin Altekoester, Noemi A Fuentes-Bolanos, Veronica Yeung iD und 32 weitere

Nature Medicine · 2024-07 · 30 (7) · 1913-1922

DOI: 10.1038/s41591-024-03044-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nature Medicine, online erschienen am 06.06.2024. Verfasst von Loretta M S Lau und 43 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health | National Health and Medical Research Council (NHMRC), Cancer Institute NSW (Cancer Institute New South Wales).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which patients will benefit most from precision-guided treatment (PGT). Here we report consecutive data from 384 patients with high-risk pediatric cancer (with an expected cure rate of less than 30%) who had at least 18 months of follow-up on the ZERO Childhood Cancer Precision Medicine Program PRecISion Medicine for Children with Cancer (PRISM) trial. A total of 256 (67%) patients received PGT recommendations and 110 (29%) received a recommended treatment. PGT resulted in a 36% objective response rate and improved 2-year progression-free survival compared with standard of care (26% versus 12%; P = 0.049) or targeted agents not guided by molecular findings (26% versus 5.2%; P = 0.003). PGT based on tier 1 evidence, PGT targeting fusions or commenced before disease progression had the greatest clinical benefit. Our data show that PGT informed by comprehensive molecular profiling significantly improves outcomes for children with high-risk cancers. ClinicalTrials.gov registration: NCT03336931

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineNeoplasmsHumansChildFemaleMaleAdolescentChild, PreschoolInfantProgression-Free SurvivalTreatment Outcome

Autor:innen und Institutionen

  • Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.
  • School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Sydney, New South Wales, Australia.
  • Kids Cancer Centre, Sydney Children's Hospital, Sydney, New South Wales, Australia.
  • Children's Cancer Centre, Royal Children's Hospital, Melbourne, Victoria, Australia.
  • Department of Paediatrics, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Victoria, Australia.
  • Oncology Services Group, Children's Health Queensland Hospital & Health Service, Brisbane, Queensland, Australia.

ORCID-Profile: Loretta M S Lau, Dong-Anh Khuong-Quang, Chelsea Mayoh, Marie Wong, Sumanth Nagabushan, Veronica Yeung, Natacha Omer, Nataliya Zhukova, Louise Cui, Angela Lin, Andrew S Moore, David D Eisenstat, Nicholas G Gottardo, Wayne Nicholls, Jordan R Hansford, Rishi S Kotecha, Marion K Mateos, Vanessa Tyrrell, Michelle Haber, Toby N Trahair, Mark J Cowley, Paul G Ekert, David S Ziegler

Förderung

  • Department of Health | National Health and Medical Research Council (NHMRC)
  • Cancer Institute NSW (Cancer Institute New South Wales)

Zitieren

APA

Lau, L. M. S., Khuong-Quang, D. A., Mayoh, C., Wong, M., Barahona, P., Ajuyah, P., Senapati, A., Nagabushan, S., Sherstyuk, A., Altekoester, A. K., Fuentes-Bolanos, N. A., Yeung, V., Sullivan, A., Omer, N., Diamond, Y., Jessop, S., Battaglia, L., Zhukova, N., Cui, L., …, & Ziegler, D. S. (2024). Precision-guided treatment in high-risk pediatric cancers. Nature Medicine, 30(7), 1913-1922. https://doi.org/10.1038/s41591-024-03044-0

Vancouver

Lau LMS, Khuong-Quang DA, Mayoh C, Wong M, Barahona P, Ajuyah P, et al. Precision-guided treatment in high-risk pediatric cancers. Nature Medicine. 2024;30(7):1913-1922. doi:10.1038/s41591-024-03044-0

BibTeX
@article{Lau2024,
  author = {Lau, Loretta M S and Khuong-Quang, Dong-Anh and Mayoh, Chelsea and Wong, Marie and Barahona, Paulette and Ajuyah, Pamela and Senapati, Akanksha and Nagabushan, Sumanth and Sherstyuk, Alexandra and Altekoester, Ann-Kristin and Fuentes-Bolanos, Noemi A and Yeung, Veronica and Sullivan, Ashleigh and Omer, Natacha and Diamond, Yonatan and Jessop, Sophie and Battaglia, Lauren and Zhukova, Nataliya and Cui, Louise and Lin, Angela and Gifford, Andrew J and Fleuren, Emmy D G and Dalla-Pozza, Luciano and Moore, Andrew S and Khaw, Seong-Lin and Eisenstat, David D and Gottardo, Nicholas G and Wood, Paul J and Tapp, Heather and Alvaro, Frank and McCowage, Geoffrey and Nicholls, Wayne and Hansford, Jordan R and Manoharan, Neevika and Kotecha, Rishi S and Mateos, Marion K and Lock, Richard B and Tyrrell, Vanessa and Haber, Michelle and Trahair, Toby N and Cowley, Mark J and Ekert, Paul G and Marshall, Glenn M and Ziegler, David S},
  title = {Precision-guided treatment in high-risk pediatric cancers},
  journal = {Nature Medicine},
  year = {2024},
  volume = {30},
  number = {7},
  pages = {1913--1922},
  doi = {10.1038/s41591-024-03044-0}
}
Kostenlos starten →